Partnership will Leverage Complementary
Expertise in Applied Biology and Engineering to Create and
Enhance Multiple Digital Biology Platform
Companies
WILMINGTON,
Mass. and CAMBRIDGE,
Mass., July 25, 2024 /PRNewswire/ -- Analog
Devices, Inc. (Nasdaq: ADI), a global semiconductor
leader, and Flagship Pioneering, the bioplatform innovation
company, today announced a strategic alliance to accelerate the
development of a fully digitized biological world. This partnership
will bridge ADI's expertise in engineering for analog and digital
semiconductors with Flagship Pioneering's expertise in applied
biology to foster the discovery of biological insights, new and
enhanced measurements, diagnostics, and novel interventions. The
partnership represents the opportunity to create breakthrough
solutions for human health and sustainability.
Specifically, the partnership will leverage
Flagship Pioneering's unique innovation process and ADI's cutting
edge semiconductor technologies, signal processing portfolio and
physical world domain expertise to unlock deeply disruptive
solutions and create new companies in the digital biology space.
Initial areas of focus will include bioelectronic platforms,
regenerative agriculture, novel applications of AI/ML, and
preemptive health and medicine. Potential advancements may further
drive next-generation protein sequencing, multiomics, early disease
diagnostics, transformation of large biological information to
actionable digital data, drug design and optimization, and more.
This partnership is the latest in Flagship Pioneering's Enabling
Technologies Initiative, which is focused on the development of new
therapeutic modalities by enabling and powering advanced
technologies.
"At its core, ADI exists to accelerate
breakthroughs that enrich lives and the world around us," said
Vincent Roche, CEO and Chair at ADI.
"Innovative technology has the potential to enable better and more
proactive care. We expect our digital biology partnership with
Flagship Pioneering will put the Intelligent Edge at the center of
innovating data-informed health solutions for some of today's
biggest challenges."
"Fueled by technological leaps and deep
biological understanding, we have entered a new era of biomedical
and life science innovation, enabling ever-greater advances to
improve the health of humans and the planet," said Noubar Afeyan, Ph.D., Founder and CEO of
Flagship Pioneering. "Flagship and ADI have a shared ambition and
complementary strengths to accelerate the development of a fully
digitized biological world that harnesses nature's intelligence to
create solutions for preventative and therapeutic medicines,
regenerative agriculture, and threats from climate change."
The partnership will be fueled by Flagship
Pioneering's origination process for pioneering and scaling novel
technologies and/or biological insights that have led to new types
of therapeutic modalities such as mRNA, tRNA, and epigenetic
controllers. ADI's current applications of sensor technologies,
microfabrication technologies, and automation for healthcare
including diagnostics, imaging, therapeutic devices, and continuous
monitoring will underpin the combinatorial innovation driven
through this engagement. Flagship Pioneering's
scientist-entrepreneurs will partner with ADI's scientists and
engineers to conceive and create new bioplatforms that build on
capabilities to bridge biology and technology, advancing novel
human health and sustainability innovations.
About Analog Devices
Analog Devices,
Inc. (NASDAQ: ADI) is a global semiconductor leader that
bridges the physical and digital worlds to enable breakthroughs at
the Intelligent Edge. ADI combines analog, digital, and software
technologies into solutions that help drive advancements in
digitized factories, mobility, and digital healthcare, combat
climate change, and reliably connect humans and the world. With
revenue of more than $12 billion in
FY23 and approximately 26,000 people globally working alongside
125,000 global customers, ADI ensures today's innovators stay Ahead
of What's Possible. Learn more at www.analog.com and
on LinkedIn and Twitter (X).
About Flagship Pioneering
Flagship
Pioneering invents and builds bioplatform companies, each with the
potential for multiple products that transform human health or
sustainability. Since its launch in 2000, Flagship has originated
and fostered more than 100 scientific ventures, resulting in more
than $75 billion in aggregate value.
To date, Flagship has deployed over $3.8
billion in capital toward the founding and growth of its
pioneering companies alongside more than $27
billion of follow-on investments from other institutions.
The current Flagship ecosystem comprises 40 companies,
including Foghorn Therapeutics (NASDAQ:
FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ:
OMGA), Sana Biotechnology (NASDAQ: SANA), Generate
Biomedicines, Inari, Indigo Agriculture, and Tessera
Therapeutics.
Media Contacts:
Analog Devices:
corpcomm@analog.com
Flagship Pioneering: press@flagshippioneering.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/analog-devices-and-flagship-pioneering-announce-strategic-partnership-to-accelerate-the-development-of-a-fully-digitized-biological-world-302206109.html
SOURCE Analog Devices, Inc.